Metrics as of 10/15/2026, 07:58 AM (Berlin time), refresh in progress.
Seres Therapeutics Stock
Seres Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard N. Kender
- Employees
- 66
- Market cap
- $24 M
- IPO
- 26/06/2015
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management…
Seres Therapeutics stock: price history
1D
-4.3%
1W
-11.0%
1M
-48.8%
6M
-72.6%
YTD
-83.7%
1Y
-87.7%
2Y
-85.5%
5Y
-98.1%
10Y
-98.9%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~21% stronger price swings than usual
Ask the agents about Seres Therapeutics
Analyst assessment of Seres Therapeutics
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
11
BUY
3
HOLD
4
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 13/03/2026
Seres Therapeutics stock metrics
P/E
-1.02
P/B
0.68
EV/EBITDA
-1.45
RETURN ON EQUITY
13.3%
NET MARGIN
622.4%
DEBT/EQUITY
1.64
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.8%
FLOAT SHARES
7,535,644
AVG. DAILY VOLUME (30D)
71,357
Insider transactions (SEC)
Brady Kelly
DesRosier Thomas
DesRosier Thomas
Henn Matthew R
Henn Matthew R
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Seres Therapeutics stock
What does Seres Therapeutics do?
Seres Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard N. Kender, the company employs around 66 people.
The IPO was on 26/06/2015; the stock trades on NASDAQ under the ticker MCRB.
What do analysts say about Seres Therapeutics stock?
18 analysts rate the stock, the consensus is Buy (as of 13/03/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Seres Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 21% stronger than usual.
Does Seres Therapeutics pay a dividend?
No, Seres Therapeutics currently does not pay a dividend.
Which stocks are comparable to Seres Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Seres Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Seres Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.